Certification of interim filings - full certificate
I, Douglas Janzen, President and Chief Executive Officer of Cardiome Pharma Corp., certify the following:
Date: August 13, 2010
President and Chief Executive Officer
Review: I have reviewed the interim financial statements and interim MD&A (together, the “interim
filings”) of Cardiome Pharma Corp. (the “issuer”) for the interim period ended June 30, 2010.
No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim
filings do not contain any untrue statement of a material fact or omit to state a material fact required to be
stated or that is necessary to make a statement not misleading in light of the circumstances under which it
was made, with respect to the period covered by the interim filings.
Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial
statements together with the other financial information included in the interim filings fairly present in all
material respects the financial condition, results of operations and cash flows of the issuer, as of the date of
and for the periods presented in the interim filings.
Responsibility: The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those
terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and
Interim Filings, for the issuer.
Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying
officer(s) and I have, as at the end of the period covered by the interim filings
designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance
material information relating to the i